NEW YORK (GenomeWeb) – Caribou Biosciences today announced that it has closed an $11 million Series A financing round.

Investors included Fidelity Biosciences, Novartis, Mission Bay Capital, 5 Prime Ventures, and one undisclosed partner. Caribou co-founder and pioneering CRISPR/Cas9 researcher Jennifer Doudna has also joined as an investor, the firm said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.